The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01262118?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
